Fighting drug resistant TB requires expertise and innovation. TB CARE II is tackling this need by working with TB policy makers and implementers to develop a network of experts and resources to strengthen national and regional drug resistant TB programs. Building from the expertise available through Partners In Health Technical Assistance Centers (TAC) in Lesotho, Russia and Peru (through PIH sister organization Socios En Salud), TB CARE II is working to support the development of TACs so we can share experiences to build effective PMDT worldwide.
Programmatic Management of Drug-resistant TB (PMDT): While the causes of multi-drug resistant TB are similar in all high burden countries
(low adherence, weak DOTS, poor treatment compliance, inadequate drug supplies, direct transmission, etc.).
Many countries are in the process of establishing or scaling up treatment of drug-resistant tuberculosis (DR TB). Effectively scaling up treatment will require addressing health systems–related issues, such as task shifting to alleviate human resources shortages and greater community engagement. A principal challenge in establishing or scaling up treatment of DR TB is deciding what model of care to implement. A crucial step is bridging the gap between the hospital and the community to ensure continuity of care. For DR TB treatment to be truly patient-centered, patients must be supported in their homes and communities.
This report on TB drug resistance by the World Health Organization (WHO) updates “Anti-tuberculosis drug resistance in the world: Report No. 4” published by WHO in 2008. It summarizes the latest data and provides latest estimates of the global epidemic of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB). For the first time, this report includes an assessment of the progress countries are making to diagnose and treat MDR-TB cases.